Legend Biotech Corp. ADR (LEGN): Price and Financial Metrics


Legend Biotech Corp. ADR (LEGN): $40.91

-0.10 (-0.24%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add LEGN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

LEGN Stock Price Chart Interactive Chart >

Price chart for LEGN

LEGN Price/Volume Stats

Current price $40.91 52-week high $58.00
Prev. close $41.01 52-week low $30.75
Day low $40.74 Volume 825,194
Day high $41.89 Avg. volume 718,883
50-day MA $44.44 Dividend yield N/A
200-day MA $43.12 Market Cap 6.71B

Legend Biotech Corp. ADR (LEGN) Company Bio


Legend Biotech Corp. is a holding company which engages in the discovery and development of novel cell therapies for oncology and other indications. It carries out its operations through the North America, and China geographical segments. The company was founded in May 2015 and is headquartered in Somerset, NJ.


LEGN Latest News Stream


Event/Time News Detail
Loading, please wait...

LEGN Latest Social Stream


Loading social stream, please wait...

View Full LEGN Social Stream

Latest LEGN News From Around the Web

Below are the latest news stories about LEGEND BIOTECH CORP that investors may wish to consider to help them evaluate LEGN as an investment opportunity.

BMO Capital Keeps Their Buy Rating on Legend Biotech (LEGN)

In a report released today, Kostas Biliouris from BMO Capital maintained a Buy rating on Legend Biotech (LEGN - Research Report), with a price target of $77.00. The company's shares opened today at $41.09.According to TipRanks, Biliouris is a 4-star analyst with an average return of 14.6% and a 40.00% success rate. Biliouris covers the Healthcare sector, focusing on stocks such as Intellia Therapeutics, Verve Therapeutics, and Beam Therapeutics.Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $69.00.

Christine Brown on TipRanks | October 4, 2022

CARVYKTI™ (ciltacabtagene autoleucel) Receives Approval from Japan’s Ministry of Health, Labour and Welfare (MHLW) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

SOMERSET, N.J., September 27, 2022--Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved CARVYKTI™ for the treatment of adults with relapsed or refractory MM.

Yahoo | September 27, 2022

Legend Biotech to Host 2022 R&D Day on Monday, October 3, 2022

SOMERSET, N.J., September 15, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced it will host its in-person and virtual Research & Development Day on Monday, October 3, 2022 at 10:00 a.m. ET at Andaz 5th Avenue in New York City. Please click here to register for the event.

Yahoo | September 15, 2022

Legend Biotech Stock Joins Elite Club Of Stocks With RS Ratings Over 90

Legend Biotech stock had its Relative Strength (RS) Rating upgraded from 87 to 91 Thursday. As you try to find the best stocks to buy and watch, keep a close on eye on relative price strength. Is Legend Biotech Stock A Buy?

Yahoo | September 1, 2022

Legend Biotech Announces Participation in Upcoming Investor Conferences

SOMERSET, N.J., August 19, 2022--Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today announced its participation in the upcoming investor conferences:

Yahoo | August 19, 2022

Read More 'LEGN' Stories Here

LEGN Price Returns

1-mo -6.98%
3-mo -27.01%
6-mo -1.56%
1-year -22.05%
3-year N/A
5-year N/A
YTD -12.23%
2021 65.52%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5904 seconds.